Antitubercular
This page covers all Antitubercular drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting InhA (Isoniazid target), RNA polymerase beta-subunit, InhA.
Targets
InhA (Isoniazid target) · RNA polymerase beta-subunit · InhA · ATP synthase
Phase 3 pipeline (6)
- RNTCP Category I treatment for 9months · All India Institute of Medical Sciences · Infectious Diseases
Isoniazid is a prodrug that is converted to its active form, which inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis. - RNTCP Category I treatment for 6 months · All India Institute of Medical Sciences · Infectious Diseases
Isoniazid is a prodrug that is converted into its active form, which inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis. - RIFINAH © · Assistance Publique - Hôpitaux de Paris · Infectious Diseases
Rifinah is an antitubercular medication that works by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis. - rifapentine + isoniazid · The Aurum Institute NPC · Infectious Diseases
Rifapentine inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis, while isoniazid inhibits the synthesis of mycolic acid and the metabolism of fatty acids. - Rifampin-free regimen · Nantes University Hospital · Infectious Diseases
Rifampin-free regimen involves the use of rifampicin-free antitubercular drugs to treat tuberculosis. - Tuberculosis treatment · National Institute of Allergy and Infectious Diseases (NIAID) · Infectious Disease
Isoniazid works by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis, thereby inhibiting bacterial growth and replication.
Phase 2 pipeline (1)
- Bedaquiline, Delamanid, Moxifloxacin · LigaChem Biosciences, Inc. · Infectious Disease
Inhibits Mycobacterium tuberculosis ATP synthase